ABUS vs ZKIN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 29, 2026

ABUS

48.6
AI Score
VS
ABUS Wins

ZKIN

37.5
AI Score

Investment Advisor Scores

ABUS

49score
Recommendation
HOLD

ZKIN

38score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ABUS ZKIN Winner
Revenue 14.08M 71.24M ZKIN
Net Income -33.50M -3.99M ZKIN
Net Margin -237.9% -5.6% ZKIN
Operating Income -38.16M -4.25M ZKIN
ROE -43.7% -16.3% ZKIN
ROA -35.4% -6.3% ZKIN
Total Assets 94.62M 62.87M ABUS
Cash 18.01M 2.31M ABUS
Current Ratio 15.73 1.44 ABUS

Relative Price Performance (Last 90 Days)

ABUS 1M: -10.5% · 3M: +0.9% ZKIN 1M: -11.8% · 3M: -17.8%

Current Technical Phase

ABUS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 44

RSI (14): 44.3 · Price: $4.36

ZKIN

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 39

RSI (14): 39.4 · Price: $1.20

Fundamentals Snapshot

Metric ABUS ZKIN
Market Cap
Forward P/E -35.2 0.0
Trailing P/E 5.2
Revenue (TTM)
Revenue Growth 100.5% -0.4%
Gross Margin 0.9% 0.1%
Operating Margin 0.9% -0.1%
EPS 0.83 -0.70
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ABUS is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.